Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.15
Bid: 8.80
Ask: 9.50
Change: 0.05 (0.55%)
Spread: 0.70 (7.955%)
Open: 9.10
High: 9.15
Low: 8.70
Prev. Close: 9.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

3 Dec 2012 09:30

RNS Number : 5442S
Scancell Holdings Plc
03 December 2012
 



 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Scancell Holdings Plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Share Nominees Ltd

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

29/11/12

6. Date on which issuer notified:

29/11/12

7. Threshold(s) that is/are crossed orreached: vi, vii

Above 9%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary shares of 0.1p

2,742,262

2,742,262

17,581,992

17,581,992

9.04%

GB00B63D3314

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

17,581,992

9.04%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

This follows the transfer of the Hygea VCT PLC 14,839,730 shares into Share Nominees

14. Contact name:

Peter Gregory,

Operations Manager, The Share Centre.

15. Contact telephone number:

01296 439 184

 

Note: Annex should only be submitted to the FSA not the issuer

Annex: Notification of major interests in share

A: Identity of the persons or legal entity subject to the notification obligation

Full name

(including legal form of legal entities)

 

Contact address

(registered office for legal entities)

 

Phone number & email

 

Other useful information

(at least legal representative for legal persons)

 

B: Identity of the notifier, if applicable

Full name

 

Contact address

 

Phone number & email

 

Other useful information

(e.g. functional relationship with the person or legal entity subject to the notification obligation)

C: Additional information

For notes on how to complete form TR-1 please see the FSA website.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLIFETFTLVIIF
Date   Source Headline
17th Apr 20247:00 amRNSPresenting at the Annual Immuno-Oncology Summit
16th Apr 20247:00 amRNSBlock Listing Six Monthly Return
3rd Apr 20247:00 amRNSEmployee exercise of share options
2nd Apr 20247:00 amRNSScancell to Present at 2024 AACR Annual Meeting
28th Mar 20241:21 pmRNSScancell Appoints WG as Joint Broker
26th Mar 202412:22 pmRNSFirst iSCIB1+ patient dosed
14th Mar 202411:17 amRNSAppointment of Sath Nirmalananthan to the Board
12th Mar 20247:00 amRNSScancell Attendance at Upcoming Conferences
4th Mar 20247:00 amRNSPresenting at Next-Gen Immuno-Oncology Conference
20th Feb 20247:00 amRNSChange of Auditor
5th Feb 20247:00 amRNSDirectorate Change
30th Jan 20247:00 amRNSInterim Results
26th Jan 20247:00 amRNSNotice of Interim Results and Presentation
17th Jan 20241:46 pmRNSUpdate on SCOPE trial
28th Dec 20235:36 pmRNSHolding(s) in Company
27th Dec 202311:38 amRNSHolding(s) in Company
19th Dec 20237:00 amRNSResult of the Open Offer
6th Dec 202312:41 pmRNSPDMR Notification
1st Dec 20237:00 amRNSResults of Placing
30th Nov 20235:03 pmRNSProposed Capital Raise to raise approximately £6m
29th Nov 20232:35 pmRNSResult of AGM
28th Nov 20237:00 amRNSUpdate on SCOPE trial
10th Nov 20238:32 amRNSScancell to present at 20th SMR Congress
1st Nov 20237:00 amRNSScancell to present at 38th Annual SITC meeting
31st Oct 202312:00 pmRNSNotice of AGM
31st Oct 20237:00 amRNSResults for the Year Ended 30 April 2023
20th Oct 20237:00 amRNSUpdate on Final Results
18th Oct 20237:00 amRNSScancell to speak at World Vaccine Congress Europe
17th Oct 20237:00 amRNSBlock Listing Six Monthly Return
11th Oct 20237:00 amRNSChange of Date for Final Results
3rd Oct 20237:00 amRNSNotice of Final Results and Investor Presentation
19th Sep 20237:00 amRNSPositive data from Phase 2 SCOPE trial with SCIB1
14th Sep 20237:00 amRNSScancell to present three posters at ICI
7th Sep 20237:00 amRNSScancell Appoints Head of Business Development
29th Aug 20237:00 amRNSScancell Appoints Sath Nirmalananthan as CFO
31st Jul 20237:00 amRNSModi-1 trial open for expansion in CPI combination
13th Jul 20239:14 amRNSExtension of exercise period for CEO share options
10th Jul 20237:00 amRNSPipeline strategy and business update
2nd Jun 20237:00 amRNSScancell to Present Modi-1 Data at ASCO
21st Apr 20237:00 amRNSIssue of share options to Non-Executive Directors
18th Apr 20237:00 amRNSModiFY Phase 1/2 poster presentation at AACR 2023
17th Apr 20237:00 amRNSBlock Listing Application to AIM
13th Mar 20237:00 amRNSStatement re: Silicon Valley Bank (SVB)
21st Feb 20239:05 amRNSSecond Price Monitoring Extn
21st Feb 20239:00 amRNSPrice Monitoring Extension
21st Feb 20237:00 amRNSEncouraging early efficacy data from ModiFY trial
13th Feb 20237:00 amRNSPositive response in COVIDITY trial
8th Feb 20237:00 amRNSIssue of Equity
1st Feb 20237:00 amRNSDr Jean-Michel Cosséry appointed as Chairman
25th Jan 20237:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.